Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it.

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances.

Biotech Investing: How PRVs Can Unlock Major Opportunities

Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%.

DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma.

DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024.

The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well.